Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 53:2129-2140, doi:10.1016/j.jacc.2009.02.047
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Appendix
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hage, F. G.
Right arrow Articles by Iskandrian, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hage, F. G.
Right arrow Articles by Iskandrian, A. E.
Related Collections
Right arrowRelated Article

STATE-OF-THE-ART PAPER

The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease

Fadi G. Hage, MD*,{dagger},*, Rajesh Venkataraman, MD*, Gilbert J. Zoghbi, MD*,{dagger}, Gilbert J. Perry, MD*, Angelo M. DeMattos, MD{ddagger} and Ami E. Iskandrian, MD*

* Division of Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, Alabama
{dagger} Section of Cardiology, Birmingham Veteran's Administration Medical Center, Birmingham, Alabama
{ddagger} Division of Nephrology, University of California Davis, Davis, California

Manuscript received February 10, 2009; accepted February 25, 2009.

* Reprint requests and correspondence: Dr. Fadi G. Hage, Zeigler Research Building 1024, 1530 3rd Avenue South, Birmingham, Alabama 35294-0006 (Email: fadihage{at}uab.edu).

Chronic kidney disease (CKD) affects approximately 13% of the U.S. population and is associated with increased risk of cardiovascular complications. Once renal replacement therapy became available, it became apparent that the mode of death of patients with advanced CKD was more likely than not related to cardiovascular compromise. Further observation revealed that such compromise was related to myocardial disease (related to hypertension, stiff vessels, coronary heart disease, or uremic toxins). Early on, the excess of cardiovascular events was attributed to accelerated atherosclerosis, inadequate control of blood pressure, lipids, or inflammatory cytokines, or perhaps poor glycemia control. In more recent times, outcome research has given us further information that relates even lesser degrees of renal compromise to an excess of cardiovascular events in the general population and in those with already present atherosclerotic disease. As renal function deteriorates, certain physiologic changes occur (perhaps due to hemodynamic, inflammatory, or metabolic changes) that decrease oxygen-carrying capacity of the blood by virtue of anemia, make blood vessels stiffer by altering collagen or through medial calcinosis, raise the blood pressure, increase shearing stresses, or alter the constituents of atherosclerotic plaque or the balance of thrombogenesis and thrombolysis. At further levels of renal dysfunction, tangible metabolic perturbations are recognized as requiring specific therapy to reduce complications (such as for anemia and hyperparathyroidism), although outcome research to support some of our current guidelines is sorely lacking. Understanding the process by which renal dysfunction alters the prognosis of cardiac disease might lead to further methods of treatment. This review will outline the relationship of CKD to coronary heart disease with respect to the current understanding of the traditional and nontraditional risk factors, the role of various imaging modalities, and the impact of coronary revascularization on outcome.

Key Words: chronic kidney disease • coronary heart disease • imaging • revascularization

Abbreviations and Acronyms
  CABG = coronary artery bypass grafting
  CHD = coronary heart disease
  CKD = chronic kidney disease
  CRP = C-reactive protein
  CV = cardiovascular
  DM = diabetes mellitus
  EF = ejection fraction
  ESRD = end-stage renal disease
  GFR = glomerular filtration rate
  LV = left ventricular
  LVH = left ventricular hypertrophy
  MI = myocardial infarction
  MPI = myocardial perfusion imaging
  PCI = percutaneous coronary intervention
  RT = renal transplantation


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A24. [Full Text] [PDF]



This article has been cited by other articles:


Home page
CJASNHome page
M. Wada, Y. Ueda, T. Higo, K. Matsuo, M. Nishio, A. Hirata, M. Asai, T. Nemoto, T. Kashiyama, A. Murakami, et al.
Chronic Kidney Disease and Coronary Artery Vulnerable Plaques
Clin. J. Am. Soc. Nephrol., December 1, 2011; 6(12): 2792 - 2798.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. Kendrick, A. K. Cheung, J. S. Kaufman, T. Greene, W. L. Roberts, G. Smits, M. Chonchol, and the HOST Investigators
FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic Dialysis
J. Am. Soc. Nephrol., October 1, 2011; 22(10): 1913 - 1922.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Sezai, M. Hata, T. Niino, I. Yoshitake, S. Unosawa, S. Wakui, H. Kimura, M. Shiono, T. Takayama, and A. Hirayama
Results of Low-Dose Human Atrial Natriuretic Peptide Infusion in Nondialysis Patients With Chronic Kidney Disease Undergoing Coronary Artery Bypass Grafting: The NU-HIT (Nihon University Working Group Study of Low-Dose hANP Infusion Therapy During Cardiac Surgery) Trial for CKD
J. Am. Coll. Cardiol., August 23, 2011; 58(9): 897 - 903.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
G. S. Di Marco, S. Reuter, D. Kentrup, L. Ting, L. Ting, A. Grabner, A. M. Jacobi, H. Pavenstadt, H. A. Baba, K. Tiemann, et al.
Cardioprotective effect of calcineurin inhibition in an animal model of renal disease
Eur. Heart J., August 1, 2011; 32(15): 1935 - 1945.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
Y. Shiotsu, Y. Mori, M. Nishimura, C. Sakoda, T. Tokoro, T. Hatta, N. Maki, K. Iida, N. Iwamoto, T. Ono, et al.
Plasma S100A12 Level Is Associated with Cardiovascular Disease in Hemodialysis Patients
Clin. J. Am. Soc. Nephrol., April 1, 2011; 6(4): 718 - 723.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
E. Di Angelantonio, R. Chowdhury, N. Sarwar, T. Aspelund, J. Danesh, and V. Gudnason
Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study
BMJ, September 30, 2010; 341(sep30_1): c4986 - c4986.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. B. Drueke
The five most cited NDT articles from 1999 to 2004
Nephrol. Dial. Transplant., September 1, 2010; 25(9): 2818 - 2824.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. J. Angiolillo, E. Bernardo, D. Capodanno, D. Vivas, M. Sabate, J. L. Ferreiro, M. Ueno, P. Jimenez-Quevedo, F. Alfonso, T. A. Bass, et al.
Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy
J. Am. Coll. Cardiol., March 16, 2010; 55(11): 1139 - 1146.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. L. Donadee and M. T. Gladwin
Hemodialysis Hyperhemolysis: A Novel Mechanism of Endothelial Dysfunction and Cardiovascular Risk?
J. Am. Coll. Cardiol., February 2, 2010; 55(5): 460 - 462.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement